South Korea · Delayed Price · Currency is KRW Biotoxtech Statistics
Total Valuation
Biotoxtech has a market cap or net worth of KRW 35.76 billion. The enterprise value is 64.75 billion.
| Market Cap | 35.76B |
| Enterprise Value | 64.75B |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biotoxtech has 15.72 million shares outstanding. The number of shares has decreased by -2.19% in one year.
| Current Share Class | 15.72M |
| Shares Outstanding | 15.72M |
| Shares Change (YoY) | -2.19% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 15.48% |
| Owned by Institutions (%) | n/a |
| Float | 10.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.68 |
| PB Ratio | 1.60 |
| P/TBV Ratio | 1.14 |
| P/FCF Ratio | 18.82 |
| P/OCF Ratio | 6.46 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 34.07 |
Financial Position
The company has a current ratio of 0.54, with a Debt / Equity ratio of 3.05.
| Current Ratio | 0.54 |
| Quick Ratio | 0.39 |
| Debt / Equity | 3.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | 35.97 |
| Interest Coverage | -0.82 |
Financial Efficiency
Return on equity (ROE) is -26.90% and return on invested capital (ROIC) is -7.26%.
| Return on Equity (ROE) | -26.90% |
| Return on Assets (ROA) | -2.20% |
| Return on Invested Capital (ROIC) | -7.26% |
| Return on Capital Employed (ROCE) | -13.06% |
| Weighted Average Cost of Capital (WACC) | 6.62% |
| Revenue Per Employee | 279.13M |
| Profits Per Employee | -21.25M |
| Employee Count | 188 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 4.03 |
Taxes
In the past 12 months, Biotoxtech has paid 1.22 billion in taxes.
| Income Tax | 1.22B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.24% in the last 52 weeks. The beta is 0.48, so Biotoxtech's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -29.24% |
| 50-Day Moving Average | 2,256.66 |
| 200-Day Moving Average | 2,698.28 |
| Relative Strength Index (RSI) | 42.13 |
| Average Volume (20 Days) | 8,872 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biotoxtech had revenue of KRW 52.48 billion and -3.99 billion in losses. Loss per share was -258.69.
| Revenue | 52.48B |
| Gross Profit | 7.39B |
| Operating Income | -4.62B |
| Pretax Income | -5.90B |
| Net Income | -3.99B |
| EBITDA | -158.77M |
| EBIT | -4.62B |
| Loss Per Share | -258.69 |
Balance Sheet
The company has 29.26 billion in cash and 68.36 billion in debt, with a net cash position of -39.10 billion or -2,487.39 per share.
| Cash & Cash Equivalents | 29.26B |
| Total Debt | 68.36B |
| Net Cash | -39.10B |
| Net Cash Per Share | -2,487.39 |
| Equity (Book Value) | 22.38B |
| Book Value Per Share | 2,109.86 |
| Working Capital | -44.44B |
Cash Flow
In the last 12 months, operating cash flow was 5.54 billion and capital expenditures -3.64 billion, giving a free cash flow of 1.90 billion.
| Operating Cash Flow | 5.54B |
| Capital Expenditures | -3.64B |
| Depreciation & Amortization | 4.46B |
| Net Borrowing | 639.31M |
| Free Cash Flow | 1.90B |
| FCF Per Share | 120.90 |
Margins
Gross margin is 14.07%, with operating and profit margins of -8.81% and -7.61%.
| Gross Margin | 14.07% |
| Operating Margin | -8.81% |
| Pretax Margin | -11.24% |
| Profit Margin | -7.61% |
| EBITDA Margin | -0.30% |
| EBIT Margin | -8.81% |
| FCF Margin | 3.62% |
Dividends & Yields
Biotoxtech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.19% |
| Shareholder Yield | 2.19% |
| Earnings Yield | -11.17% |
| FCF Yield | 5.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biotoxtech has an Altman Z-Score of 0.06 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.06 |
| Piotroski F-Score | 5 |